InflaRx COVID injection gets US FDA's emergency-use authorization
04/04/2023 20:51
April 4 (Reuters) - The U.S. Food and Drug
Administration (FDA) on Tuesday granted emergency-use
authorization to Inflarx NV's IF0G.F monoclonal antibody for
the treatment of hospitalized COVID patients when initiated
within 48 hours of receiving artificial life support.
(Reporting by Sriparna Roy in Bengaluru; Editing by Devika
Syamnath)
((Sriparna.Roy@thomsonreuters.com;))
Recent news on Inflarx NV
See all newsBrief: Inflarx NV Files For Offerng Of Ordinary Shares, Size Not Disclosed - SEC Filing
Brief: InflaRx Reports Full Year 2025 Results And Highlights Key Achievements And Expected Milestones
Brief: Inflarx Announces Late-Breaker Oral Presentation On Vilobelimab Phase 3 Results In Pyoderma Gangrenosum At 2026 American Academy Of Dermatology Annual Meeting
Brief: Inflarx NV Executing 30% Workforce Reduction
Brief: Inflarx Provides Update On Phase 3 Data Analyses For Vilobelimab In Pyoderma Gangrenosum